Q6NZQ4
PR
Gene name |
Paxip1 (Ptip) |
Protein name |
PAX-interacting protein 1 |
Names |
PAX transactivation activation domain-interacting protein |
Species |
Mus musculus (Mouse) |
KEGG Pathway |
mmu:55982 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
1 structures for Q6NZQ4
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| AF-Q6NZQ4-F1 | Predicted | AlphaFoldDB |
39 variants for Q6NZQ4
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs3388750624 | 82 | C>R | No | EVA | |
| rs3388732782 | 101 | G>* | No | EVA | |
| rs3388738418 | 141 | V>L | No | EVA | |
| rs3395329484 | 145 | K>* | No | EVA | |
| rs3388750168 | 154 | K>N | No | EVA | |
| rs3388750176 | 161 | V>F | No | EVA | |
| rs3388738399 | 170 | V>G | No | EVA | |
| rs239071943 | 187 | I>V | No | EVA | |
| rs220081982 | 309 | A>V | No | EVA | |
| rs237340339 | 316 | N>S | No | EVA | |
| rs32116691 | 387 | A>T | No | EVA | |
| rs3388732789 | 567 | Q>R | No | EVA | |
| rs3388746560 | 619 | I>* | No | EVA | |
| rs3395475732 | 640 | C>W | No | EVA | |
| rs3388748463 | 657 | R>G | No | EVA | |
| rs3388732728 | 657 | R>L | No | EVA | |
| rs3388748502 | 663 | W>C | No | EVA | |
| rs3388743095 | 678 | R>Q | No | EVA | |
| rs3388750654 | 705 | D>N | No | EVA | |
| rs3388741947 | 709 | D>N | No | EVA | |
| rs3388723514 | 725 | Y>C | No | EVA | |
| rs3388755304 | 788 | V>I | No | EVA | |
| rs3388748478 | 792 | H>D | No | EVA | |
| rs3388750135 | 815 | V>E | No | EVA | |
| rs3388755244 | 827 | A>V | No | EVA | |
| rs3388746492 | 836 | A>D | No | EVA | |
| rs3388743117 | 858 | F>I | No | EVA | |
| rs3388755229 | 860 | G>V | No | EVA | |
| rs3388752640 | 872 | K>R | No | EVA | |
| rs3388743141 | 873 | L>Q | No | EVA | |
| rs3388723564 | 903 | T>K | No | EVA | |
| rs3388750640 | 911 | I>V | No | EVA | |
| rs3388748528 | 916 | W>S | No | EVA | |
| rs3388746456 | 959 | L>H | No | EVA | |
| rs3388748513 | 960 | F>S | No | EVA | |
| rs3388746078 | 963 | K>M | No | EVA | |
| rs3388735929 | 966 | Y>H | No | EVA | |
| rs3388732823 | 983 | E>K | No | EVA | |
| rs3388750575 | 1012 | I>N | No | EVA |
No associated diseases with Q6NZQ4
6 regional properties for Q6NZQ4
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| domain | BRCT domain | 8 - 93 | IPR001357-1 |
| domain | BRCT domain | 94 - 183 | IPR001357-2 |
| domain | BRCT domain | 588 - 681 | IPR001357-3 |
| domain | BRCT domain | 690 - 766 | IPR001357-4 |
| domain | BRCT domain | 845 - 934 | IPR001357-5 |
| domain | BRCT domain | 957 - 1046 | IPR001357-6 |
6 GO annotations of cellular component
| Name | Definition |
|---|---|
| chromosome | A structure composed of a very long molecule of DNA and associated proteins (e.g. histones) that carries hereditary information. |
| histone methyltransferase complex | A multimeric complex that is able to catalyze the addition of methyl groups to histone proteins. |
| MLL3/4 complex | A protein complex that can methylate lysine-4 of histone H3, and which contains either of the protein subunits MLL3 or MLL4 in mammals, or equivalent in other species. |
| nuclear matrix | The dense fibrillar network lying on the inner side of the nuclear membrane. |
| nucleoplasm | That part of the nuclear content other than the chromosomes or the nucleolus. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
No GO annotations of molecular function
| Name | Definition |
|---|---|
| No GO annotations for molecular function |
20 GO annotations of biological process
| Name | Definition |
|---|---|
| adipose tissue development | The process whose specific outcome is the progression of adipose tissue over time, from its formation to the mature structure. Adipose tissue is specialized tissue that is used to store fat. |
| cellular response to DNA damage stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating damage to its DNA from environmental insults or errors during metabolism. |
| chorion development | The biological process whose specific outcome is the progression of a chorion from an initial condition to its mature state. This process begins with the formation of the structure and ends with the mature structure. The chorion is an extraembryonic membrane. |
| DNA damage response, signal transduction by p53 class mediator | A cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage. |
| DNA recombination | Any process in which a new genotype is formed by reassortment of genes resulting in gene combinations different from those that were present in the parents. In eukaryotes genetic recombination can occur by chromosome assortment, intrachromosomal recombination, or nonreciprocal interchromosomal recombination. Interchromosomal recombination occurs by crossing over. In bacteria it may occur by genetic transformation, conjugation, transduction, or F-duction. |
| DNA repair | The process of restoring DNA after damage. Genomes are subject to damage by chemical and physical agents in the environment (e.g. UV and ionizing radiations, chemical mutagens, fungal and bacterial toxins, etc.) and by free radicals or alkylating agents endogenously generated in metabolism. DNA is also damaged because of errors during its replication. A variety of different DNA repair pathways have been reported that include direct reversal, base excision repair, nucleotide excision repair, photoreactivation, bypass, double-strand break repair pathway, and mismatch repair pathway. |
| endothelial cell migration | The orderly movement of an endothelial cell into the extracellular matrix to form an endothelium. |
| histone H3-K4 methylation | The modification of histone H3 by addition of one or more methyl groups to lysine at position 4 of the histone. |
| negative regulation of DNA-binding transcription factor activity | Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of a transcription factor, any factor involved in the initiation or regulation of transcription. |
| positive regulation of histone acetylation | Any process that activates or increases the frequency, rate or extent of the addition of an acetyl group to a histone protein. |
| positive regulation of histone H3-K36 methylation | Any process that activates or increases the frequency, rate or extent of the covalent addition of a methyl group to the lysine at position 36 of histone H3. |
| positive regulation of histone H3-K4 methylation | Any process that activates or increases the frequency, rate or extent of the covalent addition of a methyl group to the lysine at position 4 of histone H3. |
| positive regulation of isotype switching | Any process that activates or increases the frequency, rate or extent of isotype switching. |
| positive regulation of isotype switching to IgG isotypes | Any process that activates or increases the frequency, rate or extent of isotype switching to IgG isotypes. |
| positive regulation of protein ubiquitination | Any process that activates or increases the frequency, rate or extent of the addition of ubiquitin groups to a protein. |
| positive regulation of response to DNA damage stimulus | Any process that activates or increases the frequency, rate or extent of response to DNA damage stimulus. |
| positive regulation of transcription initiation by RNA polymerase II | Any process that increases the rate, frequency or extent of a process involved in starting transcription from an RNA polymerase II promoter. |
| regulation of cell cycle G2/M phase transition | Any signalling pathway that modulates the activity of a cell cycle cyclin-dependent protein kinase to modulate the switch from G2 phase to M phase of the cell cycle. |
| response to ionizing radiation | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ionizing radiation stimulus. Ionizing radiation is radiation with sufficient energy to remove electrons from atoms and may arise from spontaneous decay of unstable isotopes, resulting in alpha and beta particles and gamma rays. Ionizing radiation also includes X-rays. |
| vasculogenesis | The differentiation of endothelial cells from progenitor cells during blood vessel development, and the de novo formation of blood vessels and tubes. |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MSEPAPEVPE | ELFREVKYYA | VGDIDPQVIQ | LLKAGKAKEV | SYNALASHII | SEDGDNPEVG |
| 70 | 80 | 90 | 100 | 110 | 120 |
| EAREVFDLPV | VKPSWVTLSV | QCGALLPVNG | FSPESCQIFF | GLTACLSQVS | SEDRSALWAL |
| 130 | 140 | 150 | 160 | 170 | 180 |
| VTFHGGSCQL | NLNKKCTHLI | VPEPKGEKYE | RAVKRTSIKI | VTPDWVLDCV | SEKRRKDEAF |
| 190 | 200 | 210 | 220 | 230 | 240 |
| YHPRLIIYEE | EEEEEEEGDN | EEQDSQNEGS | TEKSSVASSA | VASPAEQPCS | PKPRAEVSKG |
| 250 | 260 | 270 | 280 | 290 | 300 |
| ELMFDDSSDS | SPEKQERSLN | WAPAEAPPLN | TAQRRLPQGK | GPGLINLCAN | VPPVPGDILP |
| 310 | 320 | 330 | 340 | 350 | 360 |
| PDMRGNLMAP | GQNLQNSERS | EILGTWSPAV | RTLRNITNNA | DIQQINRPSN | VAHILQSLSA |
| 370 | 380 | 390 | 400 | 410 | 420 |
| PTKSLEQQVA | RGQQGHPNAS | AVLFGQAKGA | PETHVLQQHH | PPQQPQQQHP | ALHLQPQIMQ |
| 430 | 440 | 450 | 460 | 470 | 480 |
| LQQQQQQQQQ | QQQQPQPYPQ | PPSHQFPQQV | HQHQFSQQQL | QFPQQPLHPQ | QQLHRPQQQL |
| 490 | 500 | 510 | 520 | 530 | 540 |
| QPFQQQHALQ | QQLHQLQQQQ | LQHHQLAQLQ | QQQQQQHNLL | QQQQQQQQLQ | RLQQQQQMQN |
| 550 | 560 | 570 | 580 | 590 | 600 |
| QAAHLSQASQ | ALQHQVLPQQ | PLQLSLQPPP | QQQQQQQLFG | HDPAVEIPEE | SFLLGCVFAI |
| 610 | 620 | 630 | 640 | 650 | 660 |
| ADYPEQMSDK | QLLATWKRII | QAHGGTVDPT | FTSRCTHLLC | ASQVSSMYTQ | ALRERKRCVT |
| 670 | 680 | 690 | 700 | 710 | 720 |
| AHWLNTVLKK | KKLMPPHRAL | HFPVAFPPGG | KPCSQHIISV | TGFVDNDRDD | LKLMAYLAGA |
| 730 | 740 | 750 | 760 | 770 | 780 |
| KYTGYLCRSN | TVLICKEPSG | LKYEKAKEWR | IPCVNAQWLG | DILLGNFEAL | RQVQYSRYTA |
| 790 | 800 | 810 | 820 | 830 | 840 |
| FNMPDPFVPT | PHLVLGLLDA | WRTPVKVTAE | LLMGVRLPPK | LKPNEVANIQ | PSSKRARIED |
| 850 | 860 | 870 | 880 | 890 | 900 |
| LPPPTKKLTP | ELTPLVLFTG | FEPVQVQQYI | KKLYILGGEV | AECTKKCTHL | IASKVTRTVK |
| 910 | 920 | 930 | 940 | 950 | 960 |
| FLTAISVVKH | IVTPDWLEEC | FKRQTFIDEQ | NYILRDAEAE | VLFSFSLEES | LKRAHVSPLF |
| 970 | 980 | 990 | 1000 | 1010 | 1020 |
| KTKYFYITPG | ICPSLATMKA | IVECAGGKVL | AKQPSFRKLM | EHKQNKSLSE | IILISCENDL |
| 1030 | 1040 | 1050 | |||
| HLCREYFARG | IDVHNAEFVL | TGVLTQTLDY | ESYKFN |